Custom Enquiry
We aim to give you a response from a qualified scientist within a hour.
Review The SDS Document
DOWNLOADProduct Details
Formula
C26H31FN4O6
MW
514.55
Purity
>97%
Solubility (DMSO Mg/MI)
10
Storage (Powder)
3 Years -20°C
Storage (Solvent)
1 Year -80°C
Indication
Kidney Cancer
Mode Of Action
inhibitor
Drug Status
Approved
Target Name
Vascular endothelial growth factor 2 (VEGFR-2)
Research Area
CANCER
Research Area Sub Group
Anticancer
Pharmacology
ENZYME-LINKED RECEPTORS
Pharmacology Area Sub Group
Kinase
Bio Chemical Notes
Sunitinib is used in the treatment of advanced renal cell carcinoma. It acts as a multi-targeted tyrosine kinase inhibitor. Ref: Journal of Clinical Oncology 2006; 24 (1); 25-35.